# Strata Critical Medical (SRTA.US)

Canonical: https://gigainvestors.com/s/SRTA

Analysis as of: 2026-10-16T07:32:05.366Z. Financial observations: FY2019–FY2025.

Listing currency: USD. Reporting currency: USD.

## Verdict

Not a wonderful business

Quality tests for Buy: not passed (profit record: fail; earnings resilience is evidence only). Published buy qualification: no.

Share price: $4.34 per share; close as of 2026-10-15.

## Checklist

### understandable: fail

- 2 revenue declines in the last 10 years (informational)

- more than 2 net loss years

- negative average operating margin

- operating margin variation exceeds 0.35

- Financial history: 7 years

- Years with declining revenue: 2

- Years with a net loss: 6

- Operating margin variation: 0.42×

Chart: Operating margin; fiscal year observations.

- FY2019: -0.37×

- FY2020: -0.44×

- FY2021: -0.48×

- FY2022: -0.37×

- FY2023: -0.30×

- FY2024: -0.14×

- FY2025: -0.11×

### moat: fail

- Years with nonpositive invested capital use equity plus debt and leases; positive earnings with no positive capital are shown above 100%.

- ROIC median below threshold

- ROIC worst years below threshold (more than 1 bad year allowed)

- ROIC, median of available years: -67.8%

- ROIC, second-lowest year: -166.9%

- Typical minus recent gross margin: -2.2 pp

- Typical gross margin (annual median): 18.7%

- Recent gross margin (lower of latest and 3-year median): 20.9%

- Years with nonpositive capital: 2

- Capital spending / revenue: 1.6%

- ROIC including acquisitions, ten-year median: -49.9%

Chart: ROIC excluding acquisitions; fiscal year observations.

- FY2019: -166.9%

- FY2020: -1017.9%

- FY2021: -6.5%

- FY2022: -69.0%

- FY2023: -67.8%

- FY2024: -30.3%

- FY2025: -13.3%

### economics: fail

- owner earnings cash conversion below threshold

- incremental invested capital return below threshold

- Cash conversion uses consolidated totals: No

- Owner earnings, five-year total: -$127M

- Net income, five-year total: -$109M

- Return on incremental invested capital: -2.7%

- Working capital / revenue, annual change: 96.3 pp

Chart: Owner earnings · five years; fiscal year observations.

- FY2021: -$40M

- FY2022: -$22M

- FY2023: -$51M

- FY2024: -$52M

- FY2025: $37M

### management: fail

- buybacks unrelated to price (informational)

- ROIC first 3 years vs last 3 years: -166.9% vs -30.3%

- Per-share earnings: -0.57 to -0.35 (three-year endpoint medians)

- per-share value declined or ends nonpositive

- Management verdict uses per-share economic progress: Yes

- Ordinary dilution, 5-year annual growth: 15.0%

- Diluted shares, 5-year annual growth: 15.0%

- Per-share value change: $0.22

- Per-share value, starting three-year median: -$0.57

- Per-share value, ending three-year median: -$0.35

- Average buyback yield: 0.1%

- Buyback history: 1 years

- Debt-funded buybacks: No

- ROIC, first three-year median: -166.9%

- ROIC, last three-year median: -30.3%

Chart: Earnings per share; fiscal year observations.

- FY2019: -$1.32

- FY2020: -$0.25

- FY2021: -$0.57

- FY2022: -$0.38

- FY2023: -$0.76

- FY2024: -$0.35

- FY2025: $0.50

### accounting: fail

- Sloan accruals exceed 10%

- latest-year receivables to sales index (DSRI) exceeds 1.465

- earnings not backed by cash

- Sloan accruals: 27.7%

- Receivables to sales index (DSRI): 2.33×

- Restructuring years, last five: 0

- Earnings backed by cash: No

- Operating cash / earnings: -1.18×

- Accounting red flags: 2

- Goodwill and intangibles / equity: 0.49×

Chart: Sloan accruals; fiscal year observations.

- FY2019: -0.2%

- FY2020: 3.7%

- FY2021: -7.3%

- FY2022: 3.0%

- FY2023: -8.0%

- FY2024: -9.7%

- FY2025: 27.7%

## Holders

- [Daniel Loeb](https://gigainvestors.com/tp): tracked 13F investor; follow the investor page for holding quarter and amounts.

## Price story

Down 54% since Oct 2021 · sales -20.7%

Story as of 2026-10-16T09:59:37.627Z; price observation 2026-10-15.

### Sales · FY2024–2025

sales -20.7%; source https://www.sec.gov/Archives/edgar/data/1779128/000162828026013628/blde-20251231.htm; observed 2026-03-03.

- FY2019: $31M 

- FY2020: $23M 

- FY2021: $51M 

- FY2022: $146M 

- FY2023: $225M 

- FY2024: $249M 

- FY2025: $197M 

### Gross margin · FY2025

gross margin 20.9%; source https://www.sec.gov/Archives/edgar/data/1779128/000162828026013628/blde-20251231.htm; observed 2026-03-03.

- FY2019: 15.1% 

- FY2020: 9.9% 

- FY2021: 20.8% 

- FY2022: 15.2% 

- FY2023: 18.7% 

- FY2024: 23.7% 

- FY2025: 20.9% 

## Owner memo

Memo as of 2026-10-16T08:06:05.509Z.

### How it makes money

Operates in medical care facilities; annual sales are USD 197.1 million.

- Source: https://www.sec.gov/Archives/edgar/data/1779128/000162828026013628/blde-20251231.htm (filed 2026-03-03); FY2025: revenue 197141000; grossProfit 41126000; margin = grossProfit / revenue.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-10-05); SRTA.US: Strata Critical Medical, Inc. provides time-critical logistics and medical services to the healthcare industry in the United States. It operates in two segments, Logistics and Clinical. The company offers logistics services, such as air and ground transportation for human organs, transplant teams, and related medical materials and organ placement services; transplant clinical services, including organ recovery procedures, normothermic regional perfusion, and preservation services. It also provides other clinical services comprising cardiac perfusion services, blood management and autotransfusion services, extracorporeal membrane oxygenation services, perfusion staffing, and equipment rentals. The company was formerly known as Blade Air Mobility, Inc. and changed its name to Strata Critical Medical, Inc. in August 2025. The company was founded in 2014 and is headquartered in New York, New York.

### Why customers stay

Margins ranged from 18.7% to 23.7% during 2023–25; it lost 67.8% on its capital.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-03-03); FY2023: grossProfit / revenue = 18.7%.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-03-03); FY2024: grossProfit / revenue = 23.7%.

- Source: https://www.sec.gov/Archives/edgar/data/1779128/000162828026013628/blde-20251231.htm (filed 2026-03-03); FY2025: grossProfit / revenue = 20.9%.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-03-03); 7-year return on capital observations [[2019,-1.6690140845070423],[2020,-10.178619402985074],[2021,-0.06516370122600458],[2022,-0.6898742210186303],[2023,-0.6780800151209677],[2024,-0.302551673533894],[2025,-0.1328353819073553]]; median -0.6780800151209677. ROIC follows the displayed moat series; financial companies use return on tangible equity.

### Where the cash goes

Paid no dividends in 7 years.

- Source: https://www.sec.gov/Archives/edgar/data/1779128/000162828026013628/blde-20251231.htm (filed 2026-03-03); FY2025: growth capex 0; upkeep 11010000; cash acquisitions 66535000; owner earnings 37237000. Growth capex plus acquisitions / owner earnings = 1.7867980771812981.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-03-03); Dividend observations: [[2019,0],[2020,0],[2021,0],[2022,0],[2023,0],[2024,0],[2025,0]]. Zero only counted when supported by a complete cash-flow statement.

### Are managers owners

Insiders own 14.3% of the company.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-10-05); SRTA.US SharesStats.PercentInsiders = 14.319 percentage points; cache date 2026-10-05.

### What the price says

The price is 1.8 times annual sales.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-03-03); Closing price 4.34 USD; reporting-to-trading FX 1; FY2025 annual sales per share 2.401454118529566; price multiple 1.807238358839612. FY2025 cash earnings/share 0.45359893178834154. Closing-price date 2026-10-15.

## Monthly share-price history (USD per share)

- 2019-11: $9.78 per share

- 2019-12: $9.83 per share

- 2020-01: $10.00 per share

- 2020-02: $9.95 per share

- 2020-03: $9.67 per share

- 2020-04: $9.72 per share

- 2020-05: $9.75 per share

- 2020-06: $9.97 per share

- 2020-07: $10.10 per share

- 2020-08: $9.96 per share

- 2020-09: $10.05 per share

- 2020-10: $9.90 per share

- 2020-11: $9.97 per share

- 2020-12: $11.08 per share

- 2021-01: $14.75 per share

- 2021-02: $15.27 per share

- 2021-03: $10.29 per share

- 2021-04: $9.95 per share

- 2021-05: $9.72 per share

- 2021-06: $10.50 per share

- 2021-07: $7.67 per share

- 2021-08: $8.51 per share

- 2021-09: $10.40 per share

- 2021-10: $9.47 per share

- 2021-11: $8.79 per share

- 2021-12: $8.83 per share

- 2022-01: $6.11 per share

- 2022-02: $7.50 per share

- 2022-03: $8.49 per share

- 2022-04: $8.61 per share

- 2022-05: $6.89 per share

- 2022-06: $4.46 per share

- 2022-07: $5.56 per share

- 2022-08: $5.16 per share

- 2022-09: $4.03 per share

- 2022-10: $4.50 per share

- 2022-11: $4.92 per share

- 2022-12: $3.58 per share

- 2023-01: $4.46 per share

- 2023-02: $4.65 per share

- 2023-03: $3.38 per share

- 2023-04: $2.62 per share

- 2023-05: $3.23 per share

- 2023-06: $3.94 per share

- 2023-07: $4.17 per share

- 2023-08: $3.19 per share

- 2023-09: $2.59 per share

- 2023-10: $2.13 per share

- 2023-11: $3.17 per share

- 2023-12: $3.53 per share

- 2024-01: $2.98 per share

- 2024-02: $3.18 per share

- 2024-03: $2.85 per share

- 2024-04: $3.19 per share

- 2024-05: $3.01 per share

- 2024-06: $3.48 per share

- 2024-07: $3.30 per share

- 2024-08: $3.13 per share

- 2024-09: $2.94 per share

- 2024-10: $3.60 per share

- 2024-11: $4.74 per share

- 2024-12: $4.25 per share

- 2025-01: $3.85 per share

- 2025-02: $3.38 per share

- 2025-03: $2.73 per share

- 2025-04: $2.65 per share

- 2025-05: $3.49 per share

- 2025-06: $4.03 per share

- 2025-07: $3.99 per share

- 2025-08: $4.37 per share

- 2025-09: $5.06 per share

- 2025-10: $5.03 per share

- 2025-11: $4.34 per share

- 2025-12: $4.81 per share

- 2026-01: $4.88 per share

- 2026-02: $4.28 per share

- 2026-03: $4.18 per share

- 2026-04: $5.02 per share

- 2026-05: $6.31 per share

- 2026-06: $5.27 per share

- 2026-07: $5.02 per share

- 2026-08: $5.66 per share

- 2026-09: $5.11 per share

- 2026-10: $4.34 per share

## Annual estimated value (USD per share)

Historical values use today's bond yield for every fiscal year

Historical values use today's FX rate into trading currency for every fiscal year

Historical values use current restated fundamentals and current commodity classification; they are not point-in-time estimates

## Sources

[Original 10-K filing](https://www.sec.gov/Archives/edgar/data/1779128/000162828026013628/blde-20251231.htm); period 2025-12-31, filed 2026-03-03.

Estimates depend on assumptions and are not guarantees or investment advice. Underlying data remains subject to its source licenses; public reading does not grant bulk redistribution rights.